lenalidomide
Commercial- Indications
- Cancer
Company intelligence / Profile preview
Dash Pharmaceuticals was a New Jersey-based pharmaceutical sales and distribution company specializing in marketing generic pharmaceutical products in the United States. In January 2022 it was acquired by Natco Pharma Inc. USA for $18 million to serve as the front-end commercial arm for Natco’s US operations. As of January 2024 all Dash-branded products transitioned to the "Natco Pharma USA" label with no change to NDC numbers or product availability. The acquisition provided Natco with direct access to US customers and expanded its presence in the world’s largest pharma market.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Dash Pharmaceuticals LLC.